Gary P Kobinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7473979/publications.pdf

Version: 2024-02-01

53939 46524 9,810 142 47 93 citations h-index g-index papers 146 146 146 14489 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia. Journal of Infectious Diseases, 2022, 225, 1852-1855.	1.9	1
2	Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine. New England Journal of Medicine, 2021, 385, e35.	13.9	244
3	Modeling host-feeding preference and molecular systematics of mosquitoes in different ecological niches in Canada. Acta Tropica, 2021, 213, 105734.	0.9	4
4	Vaccine innovation spurred by the long wait for an Ebola virus vaccine. Lancet Infectious Diseases, The, 2021, 21, 440-441.	4.6	10
5	Altered microRNA Transcriptome in Cultured Human Liver Cells upon Infection with Ebola Virus. International Journal of Molecular Sciences, 2021, 22, 3792.	1.8	12
6	Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Journal of Virology, 2021, 95, e0236820.	1.5	12
7	Plant-made vaccines and therapeutics. Science, 2021, 373, 740-741.	6.0	27
8	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	0.9	62
9	In vivo generation of collagen specific Tregs with AAV8 suppresses autoimmune responses and arthritisÂin DBA1 miceÂthrough IL10 production. Scientific Reports, 2021, 11, 18204.	1.6	O
10	Computational genomics of Torque teno sus virus and Porcine circovirus in swine samples from Canada. Research in Veterinary Science, 2021, 134, 171-180.	0.9	4
11	OUP accepted manuscript. Journal of Infectious Diseases, 2021, , .	1.9	1
12	A novel DNA platform designed for vaccine use with high transgene expression and immunogenicity. Vaccine, 2021, 39, 7175-7181.	1.7	3
13	Living with the COVID-19 pandemic: act now with the tools we have. Lancet, The, 2020, 396, 1314-1316.	6.3	18
14	Hantavirus Cardiopulmonary Syndrome in Canada. Emerging Infectious Diseases, 2020, 26, 3020-3024.	2.0	10
15	Oral Vaccination With Recombinant Vesicular Stomatitis Virus Expressing Sin Nombre Virus Glycoprotein Prevents Sin Nombre Virus Transmission in Deer Mice. Frontiers in Cellular and Infection Microbiology, 2020, 10, 333.	1.8	7
16	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	0.9	184
17	COVID-19: towards controlling of a pandemic. Lancet, The, 2020, 395, 1015-1018.	6. 3	1,193
18	Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease. Lancet Infectious Diseases, The, 2020, 20, 388-389.	4.6	3

#	Article	IF	CITATIONS
19	The Cellular Impact of the ZIKA Virus on Male Reproductive Tract Immunology and Physiology. Cells, 2020, 9, 1006.	1.8	20
20	Dual RNA-Seq characterization of host and pathogen gene expression in liver cells infected with Crimean-Congo Hemorrhagic Fever Virus. PLoS Neglected Tropical Diseases, 2020, 14, e0008105.	1.3	18
21	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. Journal of Infectious Diseases, 2019, 219, 365-374.	1.9	11
22	Increased mortality in survivors of Ebola virus disease. Lancet Infectious Diseases, The, 2019, 19, 1152-1154.	4.6	1
23	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	0.9	70
24	Incorporation of Ebola glycoprotein into HIV particles facilitates dendritic cell and macrophage targeting and enhances HIV-specific immune responses. PLoS ONE, 2019, 14, e0216949.	1.1	12
25	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	0.9	224
26	Challenges and perspectives on the use of mobile laboratories during outbreaks and their use for vaccine evaluation. Human Vaccines and Immunotherapeutics, 2019, 15, 2264-2268.	1.4	8
27	NK Cells Accumulate in Infected Tissues and Contribute to Pathogenicity of Ebola Virus in Mice. Journal of Virology, 2019, 93, .	1.5	13
28	Development and Characterization of a Sin Nombre Virus Transmission Model in Peromyscus maniculatus. Viruses, 2019, 11, 183.	1.5	18
29	New filovirus disease classification and nomenclature. Nature Reviews Microbiology, 2019, 17, 261-263.	13.6	84
30	Fluorescent Crimean-Congo hemorrhagic fever virus illuminates tissue tropism patterns and identifies early mononuclear phagocytic cell targets in Ifnar-/- mice. PLoS Pathogens, 2019, 15, e1008183.	2.1	19
31	Impact of intensive care unit supportive care on the physiology of Ebola virus disease in a universally lethal non-human primate model. Intensive Care Medicine Experimental, 2019, 7, 54.	0.9	11
32	Consequences of Pathogen Lists: Why Some Diseases May Continue to Plague Us. American Journal of Tropical Medicine and Hygiene, 2019, 100, 1052-1055.	0.6	5
33	Taxonomy of the order Mononegavirales: update 2018. Archives of Virology, 2018, 163, 2283-2294.	0.9	153
34	Intramuscular Adeno-Associated Virus–Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice. Journal of Infectious Diseases, 2018, 217, 916-925.	1.9	37
35	Reply to Reisler et al. Clinical Infectious Diseases, 2018, 66, 1480-1481.	2.9	0
36	Empowerment of Women: Closing the Medical Technologies Gender Gap. Journal of Obstetrics and Gynaecology Canada, 2018, 40, 78-83.	0.3	3

3

#	Article	IF	Citations
37	Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology, 2018, 513, 17-28.	1.1	41
38	Testing Experimental Therapies in a Guinea Pig Model for Hemorrhagic Fever. Methods in Molecular Biology, 2018, 1604, 269-278.	0.4	1
39	Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine, 2018, 36, 3079-3089.	1.7	18
40	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opinion on Biological Therapy, 2018, 18, 159-173.	1.4	35
41	Modeling Ebola Virus Transmission Using Ferrets. MSphere, 2018, 3, .	1.3	16
42	Contribution of Environment Sample-Based Detection to Ebola Outbreak Management. Journal of Infectious Diseases, 2018, 218, S292-S296.	1.9	3
43	Zika Virus Vaccines: Challenges and Perspectives. Vaccines, 2018, 6, 62.	2.1	17
44	Baited vaccines: A strategy to mitigate rodentâ€borne viral zoonoses in humans. Zoonoses and Public Health, 2018, 65, 711-727.	0.9	9
45	The Makona Variant of Ebola Virus Is Highly Lethal to Immunocompromised Mice and Immunocompetent Ferrets. Journal of Infectious Diseases, 2018, 218, S466-S470.	1.9	12
46	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Journal of Infectious Diseases, 2018, 218, S553-S564.	1.9	22
47	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. Cell Host and Microbe, 2018, 24, 221-233.e5.	5.1	182
48	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
49	Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination. Scientific Reports, 2017, 7, 43776.	1.6	31
50	Taxonomy of the order Mononegavirales: update 2017. Archives of Virology, 2017, 162, 2493-2504.	0.9	173
51	Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Scientific Reports, 2017, 7, 3390.	1.6	14
52	DNA vaccination protects mice against Zika virus-induced damage to the testes. Nature Communications, 2017, 8, 15743.	5.8	90
53	Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection. Methods in Molecular Biology, 2017, 1628, 273-282.	0.4	2
54	The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy, 2017, 9, 435-450.	1.0	20

#	Article	IF	Citations
55	Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends in Molecular Medicine, 2017, 23, 820-830.	3.5	17
56	Human Zika infection induces a reduction of IFN- \hat{l}^3 producing CD4 T-cells and a parallel expansion of effector VÎ 2 T-cells. Scientific Reports, 2017, 7, 6313.	1.6	35
57	Therapeutics Against Filovirus Infection. Current Topics in Microbiology and Immunology, 2017, 411, 263-290.	0.7	3
58	Implementation of Objective PASC-Derived Taxon Demarcation Criteria for Official Classification of Filoviruses. Viruses, 2017, 9, 106.	1.5	22
59	MicroRNA and mRNA Dysregulation in Astrocytes Infected with Zika Virus. Viruses, 2017, 9, 297.	1.5	61
60	Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. AIDS Research and Therapy, 2017, 14, 55.	0.7	20
61	How to turn competitors into collaborators. Nature, 2017, 541, 283-285.	13.7	3
62	Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient. PLoS Pathogens, 2017, 13, e1006065.	2.1	14
63	Successful Control of Ebola Virus Disease: Analysis of Service Based Data from Rural Sierra Leone. PLoS Neglected Tropical Diseases, 2016, 10, e0004498.	1.3	22
64	Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. Journal of Virology, 2016, 90, 7618-7627.	1.5	32
65	Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Science Translational Medicine, 2016, 8, 329ra33.	5.8	78
66	Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Science Translational Medicine, 2016, 8, 369ra179.	5.8	194
67	Vaccines against †the other†< i>Ebolavirus < i>species. Expert Review of Vaccines, 2016, 15, 1093-1100.	2.0	6
68	Taxonomy of the order Mononegavirales: update 2016. Archives of Virology, 2016, 161, 2351-2360.	0.9	407
69	Diagnosis and management of Ebola samples in the laboratory. Expert Review of Anti-Infective Therapy, 2016, 14, 557-567.	2.0	9
70	Overlooking the importance of immunoassays – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 1110.	4.6	0
71	Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection. Journal of Infectious Diseases, 2016, 214, 1975-1979.	1.9	14
72	Syrian Hamsters as a Small Animal Model for Emerging Infectious Diseases: Advances in Immunologic Methods. Advances in Experimental Medicine and Biology, 2016, 972, 87-101.	0.8	24

#	Article	IF	CITATIONS
73	Efficacy of Vesicular Stomatitis Virus–Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona. Journal of Infectious Diseases, 2016, 214, S360-S366.	1.9	62
74	PlasmodiumParasitemia Associated With Increased Survival in Ebola Virus–Infected Patients. Clinical Infectious Diseases, 2016, 63, 1026-1033.	2.9	42
75	Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection. Scientific Reports, 2016, 6, 24179.	1.6	33
76	Pathogenicity Comparison Between the Kikwit and Makona Ebola Virus Variants in Rhesus Macaques. Journal of Infectious Diseases, 2016, 214, S281-S289.	1.9	30
77	Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Scientific Reports, 2016, 6, 30497.	1.6	11
78	More Challenges From Ebola: Infection of the Central Nervous System. Journal of Infectious Diseases, 2016, 214, S294-S296.	1.9	15
79	In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines, 2016, 1, 16021.	2.9	118
80	Possibility and Challenges of Conversion of Current Virus Species Names to Linnaean Binomials. Systematic Biology, 2016, 66, syw096.	2.7	17
81	Human Adaptation of Ebola Virus during the West African Outbreak. Cell, 2016, 167, 1079-1087.e5.	13.5	180
82	Ebola virus is unlikely to become endemic in West Africa. Nature Microbiology, 2016, 1, 16007.	5.9	3
83	Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. Journal of Virology, 2016, 90, 9209-9223.	1.5	63
84	Ebola Laboratory Response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014–2015. Journal of Infectious Diseases, 2016, 214, S169-S176.	1.9	24
85	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Reports, 2016, 15, 1514-1526.	2.9	80
86	Essentials of filoviral load quantification. Lancet Infectious Diseases, The, 2016, 16, e134-e138.	4.6	13
87	Progression of Ebola Therapeutics During the 2014–2015 Outbreak. Trends in Molecular Medicine, 2016, 22, 164-173.	3.5	67
88	Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. Antiviral Research, 2016, 126, 55-61.	1.9	11
89	Antibody therapeutics for Ebola virus disease. Current Opinion in Virology, 2016, 17, 45-49.	2.6	45
90	Nipah Virus Matrix Protein Influences Fusogenicity and Is Essential for Particle Infectivity and Stability. Journal of Virology, 2016, 90, 2514-2522.	1.5	34

#	Article	IF	Citations
91	Diagnostic strategies for Ebola virus detection. Lancet Infectious Diseases, The, 2016, 16, 294-295.	4.6	6
92	Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Research, 2016, 127, 20-31.	1.9	41
93	Development and Characterization of a Guinea Pig-Adapted Sudan Virus. Journal of Virology, 2016, 90, 392-399.	1.5	42
94	A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Neglected Tropical Diseases, 2016, 10, e0004364.	1.3	48
95	The emergence of antibody therapies for Ebola. Human Antibodies, 2015, 23, 49-56.	0.6	37
96	Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infectious Diseases, 2015, 15, 432.	1.3	36
97	Pandemic Swine-Origin H1N1 Influenza Virus Replicates to Higher Levels and Induces More Fever and Acute Inflammatory Cytokines in Cynomolgus versus Rhesus Monkeys and Can Replicate in Common Marmosets. PLoS ONE, 2015, 10, e0126132.	1.1	22
98	Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. Journal of Infectious Diseases, 2015, 212, S435-S442.	1.9	9
99	Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick. JAMA - Journal of the American Medical Association, 2015, 313, 1249.	3.8	82
100	Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals. Antiviral Research, 2015, 116, 17-19.	1.9	17
101	Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. Journal of Infectious Diseases, 2015, 212, S389-S397.	1.9	18
102	Personal Protective Equipment for Filovirus Epidemics: A Call for Better Evidence. Journal of Infectious Diseases, 2015, 212, S98-S100.	1.9	40
103	Backs against the Wall: Novel and Existing Strategies Used during the 2014-2015 Ebola Virus Outbreak. Clinical Microbiology Reviews, 2015, 28, 593-601.	5.7	42
104	Nanozyme-strip for rapid local diagnosis of Ebola. Biosensors and Bioelectronics, 2015, 74, 134-141.	5.3	320
105	Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus–Infected Nonhuman Primates. Journal of Infectious Diseases, 2015, 212, S379-S383.	1.9	18
106	Ebola Virus Transmission in Guinea Pigs. Journal of Virology, 2015, 89, 1314-1323.	1.5	46
107	VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science, 2015, 349, 739-742.	6.0	213
108	Transmission of Ebola Viruses: What We Know and What We Do Not Know. MBio, 2015, 6, e00137.	1.8	169

#	Article	IF	CITATIONS
109	Long-Term Correction of Sandhoff Disease Following Intravenous Delivery of rAAV9 to Mouse Neonates. Molecular Therapy, 2015, 23, 414-422.	3.7	64
110	A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection. Molecular Pharmaceutics, 2015, 12, 2712-2731.	2.3	46
111	Ebolavirus Evolution: Past and Present. PLoS Pathogens, 2015, 11, e1005221.	2.1	58
112	Antibody therapy for Ebola. Human Vaccines and Immunotherapeutics, 2014, 10, 964-967.	1.4	15
113	Pre-existing immunity against Ad vectors. Human Vaccines and Immunotherapeutics, 2014, 10, 2875-2884.	1.4	195
114	Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names. Viruses, 2014, 6, 3663-3682.	1.5	49
115	Longitudinal Analysis of SIVmac239 Mutations around the 12 Protease Cleavage Sites and their Correlations with Viral Load Reduction and CD4 counts. AIDS Research and Human Retroviruses, 2014, 30, A245-A246.	0.5	0
116	Targeted Prostaglandin E2 Inhibition Enhances Antiviral Immunity through Induction of Type I Interferon and Apoptosis in Macrophages. Immunity, 2014, 40, 554-568.	6.6	171
117	Sequences Surrounding the 12 Protease Cleavage Sites are Good Targets for Both Prophylactic and Therapeutic HIV Vaccines. AIDS Research and Human Retroviruses, 2014, 30, A246-A246.	0.5	0
118	Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17182-17187.	3.3	173
119	R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells. Molecular Therapy - Nucleic Acids, 2014, 3, e151.	2.3	8
120	Establishment and Characterization of a Lethal Mouse Model for the Angola Strain of Marburg Virus. Journal of Virology, 2014, 88, 12703-12714.	1.5	46
121	Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine, 2014, 32, 5722-5729.	1.7	66
122	Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 2014, 514, 47-53.	13.7	883
123	Experimental countermeasures against Ebola virus: current progress and an ethical conundrum. Cmaj, 2014, 186, 1129-1130.	0.9	1
124	Post-exposure therapy of filovirus infections. Trends in Microbiology, 2014, 22, 456-463.	3.5	58
125	Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine, 2014, 32, 2833-2842.	1.7	41
126	Novel Adeno-associated Viruses Derived From Pig Tissues Transduce Most Major Organs in Mice. Scientific Reports, 2014, 4, 6644.	1.6	23

#	Article	IF	CITATIONS
127	Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory. Scientific Reports, 2014, 4, 5824.	1.6	39
128	Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus. Scientific Reports, 2014, 4, 6881.	1.6	90
129	Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. Science Translational Medicine, 2012, 4, 158ra146.	5.8	135
130	Transmission of Ebola virus from pigs to non-human primates. Scientific Reports, 2012, 2, 811.	1.6	149
131	Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies. Science Translational Medicine, 2012, 4, 138ra81.	5.8	274
132	Ebola GP-Specific Monoclonal Antibodies Protect Mice and Guinea Pigs from Lethal Ebola Virus Infection. PLoS Neglected Tropical Diseases, 2012, 6, e1575.	1.3	90
133	Replication, Pathogenicity, Shedding, and Transmission of Zaire ebolavirus in Pigs. Journal of Infectious Diseases, 2011, 204, 200-208.	1.9	113
134	Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus. Journal of Infectious Diseases, 2010, 201, 1000-1006.	1.9	58
135	Recent advances in <i>Ebolavirus</i> vaccine development. Hum Vaccin, 2010, 6, 439-449.	2.4	44
136	Mucosal Delivery of Adenovirusâ€Based Vaccine Protects against Ebola Virus Infection in Mice. Journal of Infectious Diseases, 2007, 196, S413-S420.	1.9	53
137	Human Immunodeficiency Viral Vector Pseudotyped with the Spike Envelope of Severe Acute Respiratory Syndrome Coronavirus Transduces Human Airway Epithelial Cells and Dendritic Cells. Human Gene Therapy, 2007, 18, 413-422.	1.4	26
138	Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine, 2007, 25, 2984-2989.	1.7	102
139	Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine, 2007, 25, 5220-5231.	1.7	68
140	Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology, 2006, 346, 394-401.	1.1	121
141	Generation of an adenoviral vaccine vector based on simian adenovirus 21. Journal of General Virology, 2006, 87, 2477-2485.	1.3	46
142	Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Molecular Therapy, 2003, 8, 777-789.	3.7	105